| Document |
Document Title |
|
WO/2018/226562A1 |
A method of treating soft tissue conditions. A harvesting device is provided. The harvesting device is operably connected to a tissue processing device using tubing. An aperture is formed in a bone. The bone has an interior. The harvesti...
|
|
WO/2018/225917A1 |
The present invention relates to a means and a method for increasing the efficiency of recombinant protein expression and, more specifically, to a means and a method for optimizing the industrial production of recombinant proteins in pyr...
|
|
WO/2018/226758A2 |
This disclosure relates to populations and compositions of purified cell-derived vesicles and uses thereof. One aspect of the disclosure relates to methods for purifying the cell-derived vesicles.
|
|
WO/2018/225072A1 |
Methods of use of early apoptotic cell populations and compositions thereof disclosed herein, including methods of treating a cancer or a tumor, extending survival times of a subject suffering from a cancer or a tumor, and reducing the s...
|
|
WO/2018/227212A1 |
The present invention relates to the identification of a C90RF72 gene signature for ALS and methods of inducing the C90RF72 gene signature for ALS in neurons. Disclosed herein are methods of using the C90RF72 gene signature for screening...
|
|
WO/2018/225673A1 |
Disclosed are: a method for manufacturing a therapeutic composition containing mammalian cells, said method comprising dispersing the mammalian cells in an aqueous glucose solution having a concentration of about 3-10% or Ringer's acetat...
|
|
WO/2018/224636A1 |
The present invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle wasting occurs. The invention provides the use of inhibitors of glutamine dehydrogenase for the regenerati...
|
|
WO/2018/227101A1 |
Described are methods of enhancing development of renal organoids, methods of using the same, and kits.
|
|
WO/2018/227205A1 |
Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor cells. It is a devastating disease with a poor prognosis and an average 5 -year survival rate of about 30%. Disclosed herein are composition and metho...
|
|
WO/2018/227204A1 |
A passive, hydrodynamic technique to perform co-encapsulation of one cell-one bead in droplets is described herein. The hydrodynamic technique utilizes laminar flows and high shear liquid-liquid interfaces at a microfluidic junction to a...
|
|
WO/2018/226336A1 |
Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8+CD39+CD103+ T cells. Methods also are disclosed for isolating a nucleic acid encoding...
|
|
WO/2018/226958A1 |
Described herein are methods for producing and utilizing T cells comprising chimeric antigen receptors (CAR) comprising an extracellular domain that binds CD79b, or CD79b and CD 19. Further, this invention is related to methods of treati...
|
|
WO/2018/226435A1 |
A composition for influencing biological growth including live cells, a fluid comprising dextrose, a protectant, and a first cytokine having a first concentration within the composition as described within the present disclosure.
|
|
WO/2018/225858A1 |
Through the present invention, the CRISPR-Cas3 system is successfully established in a eukaryotic cell.
|
|
WO/2018/226638A1 |
Provided herein are Vero cell lines that stably express Herpes Simplex Virus (HSV) ICP0 protein. These cells have the same morphology of Vero cells, exhibit stable expression of HSV ICP0 protein, and also efficiently complement replicati...
|
|
WO/2018/223600A1 |
Provided in the present invention are an OCTS-CAR dual targeting chimeric antigen receptor based on OCTS technology, an encoding gene, an OCTS-CAR-T recombinant expression vector and a construction method and the use thereof. The OCTS-CA...
|
|
WO/2018/224673A1 |
The present invention relates to a method for reducing the amount of acidic species and/or increasing the amount of basic species in a composition comprising a recombinant protein or for increasing the size of mammalian cells expressing ...
|
|
WO/2018/225703A1 |
The purpose of the present invention is to provide: a method for purifying differentiation-induced cells derived from pluripotent stem cells; differentiation-induced cells purified by using the method; a sheet-shaped cell culture contain...
|
|
WO/2018/225781A1 |
The purpose of the present invention is to provide a monoclonal antibody that functions even in a state of intracellular reduction. The problem can be solved by a monoclonal antibody containing a heavy-chain variable region domain compri...
|
|
WO/2018/226640A1 |
Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving...
|
|
WO/2018/225403A1 |
This cell culturing method is characterized by irradiating cells with infrared radiation while maintaining the temperature of the cells.
|
|
WO/2018/227210A1 |
An interfacial technique utilizes hydrodynamic micro-vortices to perform (i) high efficiency single cell encapsulation and (ii) size-selective capturing of cells based on their sizes in a single microfluidic device. A notable feature of ...
|
|
WO/2018/226267A1 |
Disclosed are methods of inducing formation of a liver organoid from precursor cells, such as iPSC cells. The disclosed liver organoids may be used for screening for a serious adverse event (SAE), such as liver failure and/or drug induce...
|
|
WO/2018/225732A1 |
[Problem] To provide CAR T cells that can be used in CAR infusion therapy in which a cancer-specific intracellular antigen is used. [Solution] The problem is solved by CAR T cells for cancer therapy provided with an antibody that recogni...
|
|
WO/2018/226714A1 |
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.
|
|
WO/2018/225042A1 |
The present invention provides cell compositions, methods of production and its uses in corneal diseases. The invention discloses cell compositions and multilayer cell compositions comprising limbal epithelial cells and limbal stromal ce...
|
|
WO/2018/225802A1 |
Provided are: a method for in vitro producing spermatogenic stem cell-like cells from primordial germ cell-like cells derived from isolated pluripotent stem cells, said method comprising (1) a step for co-culturing the primordial germ ce...
|
|
WO/2018/226926A1 |
A method for revitalizing mesenchymal stem cells (MSC) maintained in culture by transducing the MSC with vectors encoding a specific gene combination, as well as methods of use of MSC so revitalized in co-culturing hematopoietic stem cells.
|
|
WO/2018/226642A1 |
The present invention provides apparatus and methods for production of tissue structures and organs. In some examples, a clean space facility may be equipped with modelling hardware and software, nanotechnology and microelectronic appara...
|
|
WO/2018/226020A2 |
The present invention relates to a humanized DR4 antibody gene having apoptosis-inducing activity, and a dual-acting chimeric antigen receptor T cell or natural killer cell therapeutic agent using the same. According to the present inven...
|
|
WO/2018/226098A2 |
The invention relates to a method for detecting antibodies against a GABAB receptor in a sample of a subject, comprising the steps of providing a sample from a subject, wherein said sample comprises, or is suspected of comprising, antibo...
|
|
WO/2018/225868A1 |
Provided is a method for predicting the differentiation potency of iPS cells in cartilage cells at the undifferentiated iPS cell-stage. Also provided is a genetic marker for predicting the differentiation potency of undifferentiated iPS ...
|
|
WO/2018/225835A1 |
A method for producing a cell laminate, said cell laminate comprising cell layers on the both faces of a porous film, by using a container consisting of a bottom and a side wall rising from the outer edge of the bottom, the porous film, ...
|
|
WO/2018/225705A1 |
The present invention addresses the problem of providing: a method for producing a cell culture containing a desired cell that is differentiated and induced from a pluripotent stem cell; a method for producing a sheet-like cell culture c...
|
|
WO/2018/227091A1 |
Described herein, in one aspect, are antigen presenting cells (APCs) comprising an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with MHC class I or...
|
|
WO/2018/223601A1 |
Provided in the present invention are an anti-PSCA and anti-PDL1 dual targeting chimeric antigen receptor based on the OCTS-CAR, an encoding gene, an OCTS-CAR-T recombinant expression vector and a construction method and use thereof. The...
|
|
WO/2018/226648A1 |
This document provides RPE cells and RPE monolayers. For example, compositions containing RPE cells or RPE monolayers as well as methods and materials for making RPE cells or RPE monolayers from, for example, stem cells (e.g., iPSCs) are...
|
|
WO/2018/227016A1 |
Systems and methods for producing cell cultured food products. The cultured food products include sushi-grade fish meat, fish surimi, foie gras, and other food types. Various cell types are utilized to produce the food products and can i...
|
|
WO/2018/225751A1 |
The present invention provides a method for maintaining and amplifying colon cancer stem cells or for inducing a colon cancer organoid. The present invention further provides a drug screening system using colon cancer stem cells maintain...
|
|
WO/2018/224761A1 |
The present invention relates to the in vitro use of at least one lectin which recognises the fucose alpha(1-2) galactose unit for labelling cancer stem cells of organs involved in respiration, in order to obtain labelled cancer stem cel...
|
|
WO/2018/223830A1 |
Provided is a preparation method of a freeze-dried human mesenchymal stem cell exosome powder, comprising the steps of: 1) culturing, purification and passaging of human mesenchymal stem cells; 2) inducing large-scale synthesis of the hu...
|
|
WO/2018/226791A1 |
A method is disclosed for treating a cancer in a subject that involves administering to the subject a therapeutically affective amount of a geranylgeranyltransferase I (GGTase I) inhibitor, such as GGTI-2418, wherein the cancer comprises...
|
|
WO/2018/226901A1 |
A living tissue model device includes: a first liquid compartment storing a liquid composition; a second liquid compartment storing a liquid composition; and a cell layered body disposed between the first liquid compartment and the secon...
|
|
WO/2018/226741A1 |
Provided is a mammalian T cell modified to express the Phf19 at a level that is higher than the level of Phf19 expressed by a T cell that has not been modified to express Phf19. Provided is a genetically-modified mammalian T cell compris...
|
|
WO/2018/226051A2 |
The present invention provides a novel serum-free medium composition for culturing cells, wherein an exosome that induces cell adhesion and proliferation is separated from a human stem cell, and the exosome is contained in a basic medium...
|
|
WO/2018/224983A1 |
The present invention relates to a method for the isolation of subpopulations of cardiac progenitor cells from a heart tissue sample, the population thus obtained and the related uses in the medical field for the cell therapy or cardiac ...
|
|
WO/2018/220442A2 |
Provided herein are stromal stem cell therapeutics and methods of use in treating disease.
|
|
WO/2018/219684A1 |
The present invention relates to a chemically defined medium for eukaryotic cell culture, comprising water, at least one carbon source, one or more vitamins, one or more salts, one or more fatty acids, one or more buffer components, sele...
|
|
WO/2018/219278A1 |
This invention provides a method for preparing CAR-T cells, comprising: providing cells comprising a chimeric antigen receptor; and culturing the cells in the presence of an agent that an extracellular domain of the CAR binds to obtain C...
|
|
WO/2018/220621A2 |
Disclosed is a composition comprising transdifferentiated human insulin producing cells (IPCs), human endothelial colony forming cells (ECFCs), and human mesenchymal stem cells (MSCs), wherein said ECFCs and MSCs enhance IPCs transdiffer...
|
